Matches in SemOpenAlex for { <https://semopenalex.org/work/W2800979781> ?p ?o ?g. }
- W2800979781 endingPage "477" @default.
- W2800979781 startingPage "467" @default.
- W2800979781 abstract "Combretastatin A4‐phosphate (CA4P) is an anti‐tumour vascular targeting agent which selectively blocks tumour blood flow. Research on CA4P in rodent tumour models is extensive; however, knowledge of its effect on spontaneous cancer is scarce. This study was conducted in canine patients with spontaneous solid tumours. The goal was to assess the toxicity and efficacy of CA4P in various spontaneous tumour types. Eight dogs with spontaneous tumours were enrolled and treated with a single dose of 75 mg m −2 intravenous CA4P. The dogs were screened and monitored before and after injection. Pre‐ and post‐treatment tumour blood flow was analysed in vivo by power Doppler ultrasound (PDUS) and contrast‐enhanced ultrasound (CEUS). Vessel destruction and tumour necrosis were evaluated by histopathology. Clinically relevant toxicity was limited to one case of temporary tetraparesis; other adverse events were mild. Significant cardiovascular changes were mostly confined to changes in heart rate and cTnI levels. Macroscopic tumour size reduction was evident in 2 dogs. Based on PDUS and CEUS, CA4P induced a significant decrease in vascular index and tumour blood flow. Post‐treatment, histopathology revealed a significant increase of necrotic tumoural tissue and a significant reduction in microvessel density in tumoural tissue. Anti‐vascular and necrotizing effects of CA4P were documented in a variety of canine spontaneous cancers with only minimal side effects. This is the first study reporting the administration of CA4P to canine cancer patients with in vivo and ex vivo assessment, and a first step toward implementing CA4P in combination therapies in veterinary oncology patients. The use of CA4P in canine patients was approved and registered by the Belgian Federal Agency for Medicines and Health Products (FAMHP) (approval number 0002588, registration number 6518 ID 2F12)." @default.
- W2800979781 created "2018-05-17" @default.
- W2800979781 creator A5006530143 @default.
- W2800979781 creator A5020574099 @default.
- W2800979781 creator A5021289466 @default.
- W2800979781 creator A5034501069 @default.
- W2800979781 creator A5037546542 @default.
- W2800979781 creator A5042692731 @default.
- W2800979781 creator A5054422444 @default.
- W2800979781 creator A5060035436 @default.
- W2800979781 creator A5061070537 @default.
- W2800979781 creator A5063844405 @default.
- W2800979781 creator A5069979334 @default.
- W2800979781 creator A5074279862 @default.
- W2800979781 date "2018-05-24" @default.
- W2800979781 modified "2023-10-14" @default.
- W2800979781 title "A single dose of intravenous combretastatin A4-phosphate is reasonably well tolerated and significantly reduces tumour vascularization in canine spontaneous cancers" @default.
- W2800979781 cites W119596808 @default.
- W2800979781 cites W1511072701 @default.
- W2800979781 cites W1780784461 @default.
- W2800979781 cites W1906647772 @default.
- W2800979781 cites W1971697005 @default.
- W2800979781 cites W197509391 @default.
- W2800979781 cites W1989217478 @default.
- W2800979781 cites W1993434718 @default.
- W2800979781 cites W1993866602 @default.
- W2800979781 cites W2004349533 @default.
- W2800979781 cites W2013713832 @default.
- W2800979781 cites W2019607817 @default.
- W2800979781 cites W2019984500 @default.
- W2800979781 cites W2020267894 @default.
- W2800979781 cites W2024264494 @default.
- W2800979781 cites W2037060916 @default.
- W2800979781 cites W2056944384 @default.
- W2800979781 cites W2059679283 @default.
- W2800979781 cites W2060110225 @default.
- W2800979781 cites W2071895235 @default.
- W2800979781 cites W2074105117 @default.
- W2800979781 cites W2088228460 @default.
- W2800979781 cites W2093517830 @default.
- W2800979781 cites W2103405873 @default.
- W2800979781 cites W2113827712 @default.
- W2800979781 cites W2115140837 @default.
- W2800979781 cites W2128560067 @default.
- W2800979781 cites W2141799694 @default.
- W2800979781 cites W2152574565 @default.
- W2800979781 cites W2152961487 @default.
- W2800979781 cites W2161943660 @default.
- W2800979781 cites W2164488259 @default.
- W2800979781 cites W2292359874 @default.
- W2800979781 cites W2338988422 @default.
- W2800979781 cites W2613610896 @default.
- W2800979781 cites W2626720204 @default.
- W2800979781 cites W336334264 @default.
- W2800979781 cites W4233016636 @default.
- W2800979781 doi "https://doi.org/10.1111/vco.12402" @default.
- W2800979781 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/29797763" @default.
- W2800979781 hasPublicationYear "2018" @default.
- W2800979781 type Work @default.
- W2800979781 sameAs 2800979781 @default.
- W2800979781 citedByCount "9" @default.
- W2800979781 countsByYear W28009797812019 @default.
- W2800979781 countsByYear W28009797812020 @default.
- W2800979781 countsByYear W28009797812021 @default.
- W2800979781 countsByYear W28009797812022 @default.
- W2800979781 countsByYear W28009797812023 @default.
- W2800979781 crossrefType "journal-article" @default.
- W2800979781 hasAuthorship W2800979781A5006530143 @default.
- W2800979781 hasAuthorship W2800979781A5020574099 @default.
- W2800979781 hasAuthorship W2800979781A5021289466 @default.
- W2800979781 hasAuthorship W2800979781A5034501069 @default.
- W2800979781 hasAuthorship W2800979781A5037546542 @default.
- W2800979781 hasAuthorship W2800979781A5042692731 @default.
- W2800979781 hasAuthorship W2800979781A5054422444 @default.
- W2800979781 hasAuthorship W2800979781A5060035436 @default.
- W2800979781 hasAuthorship W2800979781A5061070537 @default.
- W2800979781 hasAuthorship W2800979781A5063844405 @default.
- W2800979781 hasAuthorship W2800979781A5069979334 @default.
- W2800979781 hasAuthorship W2800979781A5074279862 @default.
- W2800979781 hasBestOaLocation W28009797812 @default.
- W2800979781 hasConcept C121608353 @default.
- W2800979781 hasConcept C126322002 @default.
- W2800979781 hasConcept C126838900 @default.
- W2800979781 hasConcept C142724271 @default.
- W2800979781 hasConcept C143753070 @default.
- W2800979781 hasConcept C150903083 @default.
- W2800979781 hasConcept C158846371 @default.
- W2800979781 hasConcept C197934379 @default.
- W2800979781 hasConcept C20418707 @default.
- W2800979781 hasConcept C204232928 @default.
- W2800979781 hasConcept C207001950 @default.
- W2800979781 hasConcept C2776436680 @default.
- W2800979781 hasConcept C2778275628 @default.
- W2800979781 hasConcept C2778939058 @default.
- W2800979781 hasConcept C29730261 @default.
- W2800979781 hasConcept C503630168 @default.
- W2800979781 hasConcept C544855455 @default.
- W2800979781 hasConcept C71924100 @default.